Preclinical activity of MCLA-128, an ADCC enhanced bispecific IgG1 antibody targeting the HER2: HER3 heterodimer

被引：8
|
作者：
Geuijen, Cecile
Rovers, Eric
Nijhuis, Roy
den Blanken-Smit, Renate
Visser, Therese
Bartelink, Willem
Kramer, Arjen
Zondag-van der Zande, Vanessa
Clements, Carina
Kaldenberg, Linda
Nieuwenhuizen, Nellie
van Loo, Pieter Fokko
Roovers, Rob
Gallenne, Tristan
Price, Leo
Shamsili, Setareh Van Driel
Bakker, Lex
Logtenberg, Ton
de Kruif, John
Throsby, Mark
机构：
[1] Merus, Utrecht, Netherlands
[2] OcellO, Leiden, Netherlands
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2014年 / 32卷 / 15期
关键词：
D O I：
10.1200/jco.2014.32.15_suppl.560
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
560
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Mechanism of action of MCLA-128, a humanized bispecific IgG1 antibody targeting the HER2: HER3 heterodimer
    Geuijen, Cecile
    Rovers, Eric
    Gallenne, Tristan
    Maussang-Detaille, David
    Kramer, Arjen
    Nieuwenhuizen, Nellie
    Clements, Carina
    van Zoest, Katinka
    Nijhuis, Roy
    Visser, Therese
    Den Blanken-Smit, Renate
    Bartelink, Willem
    Zondag-van der Zande, Vanessa
    Kaldenberg, Linda
    van Loo, Pieter-Fokko
    Roovers, Rob
    Doornbos, Robert
    Price, Leo
    Braam, Stefan
    van Driel, Setareh
    Bakker, Lex
    Logtenberg, Ton
    de Kruif, John
    Throsby, Mark
    CANCER RESEARCH, 2015, 75
  • [2] A Phase I/Il Study of MCLA-128, a full length IgG1 Bispecific Antibody Targeting HER2 and HER3 in Patients with Solid Tumors
    Calvo, Emiliano
    Alsina, Maria
    Schellens, Jan H. M.
    Huitema, Alwin D. R.
    Tabernero, Josep
    de Vries-Schultink, Aurelia
    Boni, Valentina
    Doger, Bernard
    Geuijen, Cecile
    Doornbos, Robert
    Bol, Kees
    Westendorp, Martine
    Throsby, Mark
    Bakker, Lex
    Shamsili, Setareh
    CANCER RESEARCH, 2016, 76
  • [3] Population Pharmacokinetics of MCLA-128, a HER2/HER3 Bispecific Monoclonal Antibody, in Patients with Solid Tumors
    Aurelia H. M. de Vries Schultink
    Kees Bol
    Robert P. Doornbos
    Anastasia Murat
    Ernesto Wasserman
    Thomas P. C. Dorlo
    Jan H. M. Schellens
    Jos H. Beijnen
    Alwin D. R. Huitema
    Clinical Pharmacokinetics, 2020, 59 : 875 - 884
  • [4] Population Pharmacokinetics of MCLA-128, a HER2/HER3 Bispecific Monoclonal Antibody, in Patients with Solid Tumors
    Schultink, Aurelia H. M. de Vries
    Bol, Kees
    Doornbos, Robert P.
    Murat, Anastasia
    Wasserman, Ernesto
    Dorlo, Thomas P. C.
    Schellens, Jan H. M.
    Beijnen, Jos H.
    Huitema, Alwin D. R.
    CLINICAL PHARMACOKINETICS, 2020, 59 (07) : 875 - 884
  • [5] First-in-human phase 1/2 study of MCLA-128, a full length IgG1 bispecific antibody targeting HER2 and HER3: Final phase 1 data and preliminary activity in HER2+metastatic breast cancer (MBC).
    Alsina, Maria
    Boni, Valentina
    Schellens, Jan H. M.
    Moreno, Victor
    Bol, Kees
    Westendorp, Martine
    Sirulnik, L. Andres
    Tabernero, Josep
    Calvo, Emiliano
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [6] Phase 2 Study of Zenocutuzumab (MCLA-128), a Bispecific HER2/HER3 Antibody in NRG1 Fusion-Positive Advanced Solid Tumors
    Schram, A.
    Macarulla, T.
    O'Reilly, E.
    Rodon, J.
    Wolpin, B.
    Ou, S.
    Kim, D.
    Yang, J. C.
    Lam, J.
    De Langen, A.
    Boni, V.
    Cerea, G.
    Duruisseaux, M.
    Felip, E.
    Liu, S.
    O'Kane, G.
    Senecal, F.
    Nagasaka, M.
    Starr, J.
    Wasserman, E.
    Drilon, A.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S675 - S675
  • [7] Translational PK-PD modeling analysis of MCLA-128, a HER2/HER3 bispecific monoclonal antibody, to predict clinical efficacious exposure and dose
    Aurelia H. M. de Vries Schultink
    Robert P. Doornbos
    Alexander B. H. Bakker
    Kees Bol
    Mark Throsby
    Cecile Geuijen
    David Maussang
    Jan H. M. Schellens
    Jos H. Beijnen
    Alwin D. R. Huitema
    Investigational New Drugs, 2018, 36 : 1006 - 1015
  • [8] Translational PK-PD modeling analysis of MCLA-128, a HER2/HER3 bispecific monoclonal antibody, to predict clinical efficacious exposure and dose
    Schultink, Aurelia H. M. de Vries
    Doornbos, Robert P.
    Bakker, Alexander B. H.
    Bol, Kees
    Throsby, Mark
    Geuijen, Cecile
    Maussang, David
    Schellens, Jan H. M.
    Beijnen, Jos H.
    Huitema, Alwin D. R.
    INVESTIGATIONAL NEW DRUGS, 2018, 36 (06) : 1006 - 1015
  • [9] Clinical proof of concept for MCLA-128, a bispecific HER2/3 antibody therapy, in NRG1 fusion-positive cancers
    Schram, Alison M.
    O'Reilly, Eileen M.
    Somwar, Romel
    Benayed, Ryma
    Shameem, Sara
    Chauhan, Thrusha
    Torrisi, Jean
    Ford, Jim
    Maussang, David
    Wasserman, Ernesto
    Ladanyi, Marc
    Hyman, David M.
    Sirulnik, L. Andres
    Drilon, Alexander
    MOLECULAR CANCER THERAPEUTICS, 2019, 18 (12)
  • [10] A phase II basket study of MCLA-128, a bispecific antibody targeting the HER3 pathway, in NRG1 fusion-positive advanced solid tumours
    Schram, A. M.
    Drilon, A.
    Macarulla Mercade, T.
    O'Reilly, E. M.
    Rodon, J. A.
    Wolpin, B. M.
    Ou, S-H. I.
    Kim, D-W.
    Yang, J. C-H.
    Lam, Y. C. J.
    Varga, A.
    de Langen, A. J.
    Witteveen, P. O.
    Boni, V.
    Cerea, G.
    Duruisseaux, M.
    Liu, S. V.
    Wasserman, E.
    Hyman, D. M.
    Tabernero, J.
    ANNALS OF ONCOLOGY, 2019, 30
12345